1993•PubMedRequires access

The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.

Kishor M. Wasan, Gabriel Lopez‐Berestein

Open publisher page 23 citations

Abstract

One of the most ambitious goals in the therapy of human diseases is developing targeted drug delivery which would allow an effective concentration of drug to reach diseased sites while sparing non-diseased tissues. One of the most extensively researched approaches in controlled drug delivery has been the incorporation of drugs into lipid carriers or phospholipid vesicles, known as liposomes. However, the behavior of lipophilic drugs and liposomes within the circulating blood remains unknown. Several laboratories have demonstrated that the pharmacokinetics, tissue distribution, and pharmacological activity of a number of drugs incorporated into liposomes are influenced by their interaction with serum lipoproteins. This chapter will examine the influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.

About this research paper

What this paper is about

One of the most ambitious goals in the therapy of human diseases is developing targeted drug delivery which would allow an effective concentration of drug to reach diseased sites while sparing non-diseased tissues. One of the most extensively researched approaches in controlled drug delivery has been the incorporation of drugs into lipid carriers or phospholipid vesicles, known as liposomes. However, the behavior of lipophilic drugs and liposomes within the circulating blood remains unknown. Several laboratories have demonstrated that the pharmacokinetics, tissue distribution, and pharmacological activity of a number of drugs incorporated into liposomes are influenced by their interaction with serum lipoproteins. This chapter will examine the influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.

Why it matters

OpenAlex reports 23 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

One of the most ambitious goals in the therapy of human diseases is developing targeted drug delivery which would allow an effective concentration of drug to reach diseased sites while sparing non-diseased tissues. One of the most extensively researched approaches in controlled drug delivery has been the incorporation of drugs into lipid carriers or phospholipid vesicles, known as liposomes. However, the behavior of lipophilic drugs and liposomes within the circulating blood remains unknown. Several laboratories have demonstrated that the pharmacokinetics, tissue distribution, and pharmacological activity of a number of drugs incorporated into liposomes are influenced by their interaction with serum lipoproteins. This chapter will examine the influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.

Key concepts: Pharmacokinetics, Pharmacology, Liposome, Drug, Pharmacodynamics, Drug carrier, Distribution (mathematics), Drug delivery

Related papers

Back to paper searchBrowse research topicsOriginal source
The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. — Research Paper | ScholarLens